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ABSTRACT 
Background:  Historically in Norway, pharmaceutical prices have been particularly high for 
originator drugs, which are produced by originator companies that have a monopoly through 
the patent system. However, once the patent expires, generic drugs are able to enter the 
market and cause a considerable decline in price. The Norwegian Medicine Agency (NoMA) 
is responsible for issuing market authorization (MA) and inclusion in the reimbursement 
scheme, for any new drugs in Norway. NoMA must evaluate the cost-effectiveness analysis 
of the originator drug provided by the pharmaceutical company. In order to predict cost- 
effectiveness, it is important to estimate how long the originator drug will stay in the market 
before generic competition is established. 
Objectives: Investigate how long it takes for a generic drug to enter the market after applying 
for MA, and what are the potential reasons for the time span used.  
Methodology: A combination of qualitative and quantitative study design. Empirically based 
and a single-case study. There were in-depth interviews conducted with executive officers at 
NoMA and representatives from generic and originator firms. The quantitative data was 
collected from the NoMA´s databases, namely Athene and P360. The data was divided into 
four phases and a statistical description of each phase was created. Furthermore each phase 
was divided into two periods 2005-08 and 2009-12 for the purpose of running a Man Whitney 
U test in order to reveal the time differences between the two periods. 
Results: For quantitative analysis the following was found: (1) For a generic medicine to 
obtain MA it takes 357 days according to median. (2) A generic drug used 131 days (median) 
to enter the market after MA approval. (3) Additionally in the second period 2009-12 it took 
longer time to obtain MA and enter the market compared to the first period of 2005-08. For 
qualitative analysis the following was discovered: (1) Various obstacles which affect the MA 
process. (2) Patent obstacles and complications which affect the overall time span. (3) 
Norway is a relatively small market and therefore less attractive for some generic companies. 
(4) Production issues and challenges faced by generic firms. (5) In some cases, the 
substitution list and reimbursement scheme processes can cause delays to the overall time 
span. (6) Once the original drug patent expires, the original firms can choose to enter the 
stepped price system and create competition for generic firms, which causes a delay in 
entering the market.  
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1. Introduction 
 
1.1 Background 
Historically pharmaceutical prices have been especially high for the originator drugs, 
produced by originator companies that have a monopoly through the patent system. However, 
after the patent expires, generic production firms can develop generic drugs with the same 
medical effect and substance as the originator drugs. When this occurs, the generic drugs are 
considerably cheaper than the original drugs, therefore providing an alternative choice with a 
big decline in price, for the consumer.  
 
Furthermore there are other mechanisms that affect the price such as the comparative drug 
mechanism, were another drug producer develops a drug with a similar effect as the originator 
but using a different chemical substance (Informant at NoMA). Moreover, there is a parallel 
import mechanism of the original drug i.e. the same drug is produced in another country in a 
cheaper manner and imported to Norway (Ot.prp. nr. 29 (1998-99)). 
 
The Norwegian Medicine Agency (NoMA) is responsible for issuing market authorization 
(MA) and inclusion in reimbursement scheme for any new drugs in Norway. To perform this 
NoMA must evaluate the cost-effectiveness analysis of the drug provided by the 
pharmaceutical company. This analysis considers a historical period of several years to 
evaluate the effects of the drug for the patients. Additionally, the analysis takes into account 
the asking price of the producer for the drug, in order to evaluate its cost-effectiveness. In 
order to predict cost- effectiveness, it is important to estimate how long the drug will stay in 
the market before generic competition is established.  
 
It would be of importance for NoMA to estimate the time span from the date the generic firms 
apply for MA until the date the generic drug enters the market. This would assist NoMA to 
predict a better price path of a comparativ drug who applies for reimbursement. This is the 
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purpose of the thesis, which to my knowledge it is being conducted for the first time in 
Norway. 
 
1.2. Objectives and hypothesis  
NoMA was interested to find out how long it takes for a generic drug to enter the market after 
it applies for MA. With the result of this paper NoMA wish to make more adequate decisions 
in evaluating the pharmacoeconomic evaluations of a new drug, especially for a comparative 
drug when it applies for reimbursement.  
 
The focus of this thesis will be to study the process of a generic drug entering the market in 
Norway. The study will also consider and estimate how long it takes for pharmaceutical 
companies to obtain Market Authorization, as well as how long it takes for a pharmaceutical 
company to launch the generic and for the stepped price system to be established. 
 
The research question of this thesis is:  
“How long does it take for generic pharmaceutical companies to obtain Market Authorization 
and enter the stepped price system?” 
The aim of the study is to analyse and describe the processes in question and evaluate if these 
processes can be formalized and utilized to predict the price path (prisbaner) when evaluating 
health economic analyses. The following sub-questions have arisen to answer the research 
question: 
1) How long does it take for a generic to enter the market after the original is 
established? 
2) How long does it takes for generic to get approved Market Authorization, how does 
this process proceed and why?  
3) How long does a generic use to enter the market after approved Market Authorization 
and why?  
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4) Is there any difference in time span of these processes between the period of the 
stepped price system establishment in 2005-08 and the period after it was well-
established in 2009-12? 
The sub-question number four is used as a hypothesis in the quantitative methodology of this 
thesis, formulated as: 
Null hypothesis: there is no difference in time spans between the periods 2005-08 and 2009-
12. 
Alternative hypothesis: there is a difference in time spans between the periods 2005-08 and 
2009-12. 
 
The motivation and policy of this thesis is based on Martin Holye’s article about the “Future 
drug prices and cost-effectiveness” where he describes that drug prices are more cost effective 
than NICE (National Institute for Health and Care Excellence in UK) stated. Generic drugs 
are one of the reasons why drug prices fall (Hoyle, 2008). 
 
1.3. Methodology  
In this paper a combination of qualitative and quantitative study design will be employed. The 
qualitative part of the study design will be descriptive. Both study designs will be based on a 
retrospective reference period. In the quantitative part of the thesis, the data is obtained for all 
the substances that entered the stepped price system from May 2005 until December 2012 
using the Norwegian Medicines Agency (NoMA) database, namely Athene and P360. For 
each phase of the overall process, an estimation of the descriptive statistic was generated and 
each phase was divided into two periods 2005-2008 and 2009-2012. The Mann Whitney U 
test was run to examine if there is a difference in time span between the two periods. 
The four phases of the overall process are:  
· The date the originator firm obtained market authorization until the date the originator 
drug entered the market. 
· The date the generic firm applied for market authorization until the date the generic 
firm obtained approval. 
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· The date the generic firm obtained market authorization until the date the generic drug 
entered the market. 
· The date the original drug entered the market until the date the generic competition 
started.  
 
Furthermore, in qualitative part of the thesis in-depth interviews were conducted with 
executive officers at NoMA who work with MA, substitution lists, the stepped price system 
and with representatives from generic and originator production firms. The purpose of the 
interviews conducted was to find out more about the system and the reasons behind each time 
span that was used for the generic products to enter the market. 
 
1.4 Structure of the thesis   
Chapter one is introduction of the thesis. The next chapter, Institutional framework, will be a 
description of the Norwegian pharmaceutical market and the mechanisms needed for a 
medicine to enter the market. Chapter 3 illustrates the institutional framework for generic 
medicines in Norway. Chapter 4 consist of motivation and policy to write this thesis. The 
methodology used to develop this paper is described in chapter 5. Results of the thesis are 
presented in chapter 6, both quantitative and qualitative. The conclusion is presented in 
chapter 7.  
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2. Institutional framework  
 
2.1. The Supply side  
The supply side consists of pharmaceutical producers, wholesalers and retail pharmacies.  
 
2.1.1 Pharmaceutical industry 
The pharmaceutical sector is extensively regulated and driven by high research and 
development (R&D). There are two types of companies on the supply side, originator 
companies and companies that manufacture generic products. The originator companies are 
responsible for R&D and managing the regulatory process of new innovative products 
required by the authorities. The responsibilities include clinical trials, MA, manufacturing, 
marketing and supply. The generic companies enter the market after the patent of the original 
product expires, as well as the data exclusivity period expires for the original product. The 
generic medical products are equivalent to the original products, but have much lower prices 
(European Commission, 2009). 
 
2.1.2. The patent of pharmaceuticals 
Pharmaceutical companies that invent new substances can apply for patent protection, which 
covers them for 20 years. However in order to develop and release a pharmaceutical product 
in the market, it may take between 8 to 12 years for a pharmaceutical company to carry out 
R&D. Therefore out of the 20 years of patent protection, the company is left with only 8 to 12 
years of monopoly in the market. Once the patent expires, generic competition can enter the 
market (Brekke, Holmås and Straume, 2007).   
 
The pharmaceutical industry generally refers to two types of patents. “Primary Patents” are 
types where the patent is concerned with the active substance. “Secondary Patents” are types 
where the patent is concerned with aspects such as the production process, different dosage 
forms or for particular pharmaceutical formulation (European Commission, 2009).    
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The European patent law system is adapted to a great extent in Norway but not fully 
applicable (Brekke, Holmås and Straume, 2007). 
 
2.1.3 Producers in Norway 
In Norway pharmaceutical industry is represented by major international companies, from 
which a few have established their own manufacturing units in the country.  The 4 main 
suppliers in 2011 were:  
· Pfizer with 9.8% of the market share  
· MSD 7.4% of the market share  
· Novatis Norge AS with 7.0 % of the market share  
· GlaxoSmithKline AS with 5.7% of the market share 
The 3 main production facilities in Norway are General Electric, Nycomed Pharma and 
Fresenius Kabi (PHIS Pharma Profile Norway, 2011). The Norwegian Association of 
Pharmaceutical Manufacturers- LMI represents most of the pharmaceutical industry, which 
are research-oriented companies in Norway (LMI, 2013).  
 
2.1.4. The wholesalers and retail pharmacies 
After the introduction of the current pharmaceutical act in 2001 the Norwegian 
pharmaceutical market developed a vertically integrated market. There are now 3 wholesalers 
with their own pharmacy chain in Norway. The law prohibits direct distribution of 
pharmaceuticals from manufacturers to the end user in general. The distribution chain to end-
users goes therefore through wholesalers and the pharmacies they own (PHIS Pharma Profile 
Norway, 2011). 
 
The below table describes the ownership structure of the wholesalers in Norway in 2011: 
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Table 2.1. Ownership structure  
Pharmaceutical 
chain 
Wholesaler Owner Market share 
Boots apotek Alliance Healthcare 
Norge AS 
Alliance Boots 
Limited (UK) 
23.7% 
Vitusapotek NMD 
Grossisthandel AS 
Celesio AG 
(German)  
47.6% 
Apotek 1 Apokjeden 
DistribusjonAS 
Tamro OY 
(Finish)/ Phoenix 
(German)  
28.9% 
Source by Apotekforeningen and PHIS Pharma Profile Norway 2011 
 
2.2. The government 
The aim of government health policies regarding pharmaceuticals is to promote correct use of 
medical products. The governmental overall objectives are: 
· Low pharmaceutical prices  
· Reliable access to efficient medical products independent of patients' ability to pay 
· Promotion of correct use of medicines both medically and economically 
The Norwegian government reimburses the use of pharmaceuticals through the National 
Insurance Scheme (NIS). Generic competition contributes to lower the prices of off-patent 
pharmaceuticals. As a result less money is spent reimbursing these medicines and there are 
more opportunities to invest in new drugs or treatments.   
 
The Ministry of Health and Care Services (MOH) is responsible for managing the 
pharmaceutical politics through law regulation in the field and reimbursement. Many of the 
tasks are delegated to the underlying professional body called the Norwegian Medicine 
Agency, NoMA (St.meld.nr 18 (2004-2005)).  
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There are two main national laws that regulate the pharmaceutical market including pricing 
and reimbursement, namely the Norwegian Pharmacies Act and the Norwegian Act on 
Medical Products (PHIS Pharma Profile Norway, 2011). 
 
2.3. The Norwegian Medicines Agency (NoMA)  
The Norwegian Medicines Agency is the underlying body of Ministry of Health and Care 
Services covering pharmaceuticals and represents Norway in European Union (EU). 
 
NoMA is responsible for approving MA for pharmaceutical products, ensuring that any 
medicine used in Norway is of high quality, is safe to use and has the adequate effect. 
Additionally, NoMA is responsible for setting the maximum pharmacy purchase prices and 
maximum reimbursement prices for affected medicines, both original and generic. 
Reimbursement decisions are made by NoMA only when expected sale for the medicine is 
less than 5 mill NOK per year in the next coming 5 years, otherwise the Storting, Norwegian 
parliament after proposal from Ministry of Health makes a decision on reimbursement. The 
pharmaceutical companies need to follow the Norwegian guidelines for pharmacoeconomic 
evaluation when applying for reimbursement (NoMAa, 2013).   
 
2.4. Market authorization (MA) 
Producers that are interested to sell their pharmaceutical products in the Norwegian market 
must apply for MA at NoMA. The requirement for the application form, its design and 
content must follow the EU requirements, as Norway is a member of the European Economic 
Area (EEA). For NoMA to be able to release the MA, the producer must document 
pharmaceutical quality, security and medical effect of the medicament. Adding to the 
submitting application the following documentation on chemical, pharmaceutical, biological, 
preclinical and clinical documentation. The MA is released only if the benefit of the medicine 
is greater than the risk posed to the patient (MOHa, 2013).  
 
There are several alternative procedures required in order to submit the application for MA. 
The pharmaceutical firm can apply for one of the procedures depending on magnitude of the 
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marked the firm is willing to enter. The procedures are: national procedure, mutual 
recognition procedure, central procedure and decentralized procedure.  Below is a summary 
of each: 
1. The National procedure: the application is submitted to one country and the MA of the 
medical product is limited only in one member state of EEA. This is the initial phase 
of the mutual recognition. For the national procedure there is a requirement of 210 
days to release MA for a product (European commission, 2005).   
2. The Mutual Recognition procedure: After granting of the national MA by an EEA 
reference member state, the producer can ask the concerned member states to issue the 
MA using the national procedure of the reference member state. For mutual 
recognition it is a requirement of 90 days to recognise the reference MA in the 
concerned member states (European commission, 2005).  
3. The Centralized procedure: the application should be submitted to the European 
Medicine Agency (EMA) for products that fall into the mandatory and optional scope 
of the centralized procedure. Two chosen member states of the EEA examine the 
application together with the expert committee of the EMA. The EMA then drafts a 
decision on MA based upon the receipt of opinion from the chosen states and 
following scientific evaluations. Norway and Iceland are an exception as they are not 
part of EU and therefore must approve the MA within 30 days after a decision is 
drafted by EMA (European commission, 2005).   
4. The Decentralized procedure: the application is directed to several member states but 
only one state is in charge of assessing the application. MA will be approved only for 
the states applied for. This procedure helps to increase the cooperation and 
effectiveness between the member states (European commission, 2005). 
 
For this phase the NoMA and the EMA are responsible for the time span used. Once the firm 
hands in the application form for MA, NoMA and EMA have 210 days to respond. The firm 
has to send in all the required documents for the application. If any documentation is lacking, 
the firm is contacted to bring in the missing documentation. In these cases the NoMA starts a 
so-called clock-stop period, which means the case will freeze until the firm responds and 
NoMA starts the clock again. The clock measures the time spent processing the application. 
In reality, the process of getting MA will exceed the 210 days, if we measure the total days 
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used between applying and receiving MA. (European commission, 2005; informant at NoMA, 
2012) 
 
Application procedures for MA are the same for generic drugs as for the original 
drugs, but in addition for generic drugs it’s a requirement to document the bio 
similar effect of the original drug (NoMAb, 2013).  
 
 
2.5. Pricing  
NoMa determines the maximal pharmacy-purchasing price for all prescription-only medicines 
in the Norwegian market. Since 2002 the price has been decided by the external reference 
price system of 9 countries including: Austria, Belgium, Denmark, Finland, Germany, 
Ireland, the Netherlands, Sweden and the United Kingdom.  The price for the Norwegian 
market will be extracted from the average of the three lowest pharmacy-purchasing prices of 
these countries. The price comparison is made per unit (tablet/dosage), since pack sizes in 
different countries are not directly comparable. Normally price changes are made once a year 
and may result in lower or higher prices. The purchasing price from producers to wholesalers 
is not regulated by the government, and the wholesalers negotiate freely the mark-up of the 
product with the production firms. The pharmacy retail price is also set at NoMA by adding 
the maximum mark-up to 7% for medicines with pharmacy-purchasing prices below 200 
NOK and up to 4% for medicines with pharmacy-purchasing prices above 200 NOK. The 
pharmacies can freely sell the medicine at a lower price than the one NoMA sets. Prices of 
generic products cannot exceed the maximum market price of the original products (PHIS 
Pharma Profile Norway, 2011). 
 
Once the medicine is granted MA, it can apply for a price at NoMA. The maximum 
processing time for price application is 90 days, however the average processing time in 2010 
was 32 days (PHIS Pharma Profile Norway, 2011). 
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2.6. Pharmaceutical Reimbursement  
Reimbursement of pharmaceuticals in Norway is one of the implements to reach the main 
governmental goals for pharmaceuticals. The government funds about 70% of the total 
pharmaceutical costs in Norway. Funding responsibilities are threefold between the Regional 
Health Authorities (RHA), the Municipalities and the National Insurance Scheme, NIS 
(Norwegian Directorate of Health a, 2012). 
 
The RHA are responsible for funding the pharmaceuticals used during the hospital stay. The 
hospitals budget covers hospital medicines. Municipalities cover the medicines for the people 
living in Long Term Care institutions (Norwegian Directorate of Health a, 2012). 
 
The NIS covers the pharmaceutical costs for out-patient care only for prescription of 
pharmaceuticals. A patient co-payment ceiling scheme was introduced in 1980s for all 
Norwegian citizens covered by NIS (Norwegian Directorate of Health, 2012). The scheme 
covers all patient costs for health care services as: doctor visit, psychologist visits, hospital 
stay, radiology department and pharmaceuticals in reimbursement scheme once the cost 
ceiling has surpassed. The cost ceiling is 2040 NOK per patient for the year 2013 (Helfo, 
2013). Norwegian patients pay out of pocket 38% of the pharmaceutical price or max 520 
NOK per prescription, until they reach the cost ceiling. Then the NIS will fund all the 
pharmaceuticals in the reimbursement scheme that surpass the cost ceiling. The purpose of the 
scheme is to get a small contribution from patients in order to avoid unnecessary use of health 
care resources (Norwegian Directorate of Health a, 2012). 
 
For all new medicines that enter the Reimbursement Scheme, NoMA makes an assessment of 
cost effective analysis made by the pharmaceutical producer. NoMA is allowed to grant 
reimbursement for a medicine if the cost of reimbursement does not exceed the Norwegian so 
called “bagatellgrensen”. Bagatellgrensen is a ceiling of 5 million NOK costs in 
reimbursement per year in the 5 coming years for the particular medicine. Medicines that 
require funding above this ceiling are sent to the Ministry of Health and Care Services in 
order to make the assessment of cost effectiveness and the final decision of funding the 
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medicine in comparison with other needs in all sectors of the country (St.meld.nr.18 (2004-
2005)). 
 
The criteria for granting reimbursement for new medicines is defined by the Norwegian 
Pharmacies Act, paragraph 9, listed below:  
1. The medicine should be used for treatment of a serious disease or risk factors that 
most likely will cause or worsen the disease.   
2. The disease in question or its risk factor will necessitate the need for repeated 
treatment over a long period. 
3. The medicine is scientifically well documented and has a clinically relevant effect in a 
defined patient population.  
4. The cost of using the new medicine is reasonable compared to the treatment value  
5. The cost associated with alternative treatment (St.meld.nr.18 (2004-2005)). 
 
Generic medicines will enter the reimbursement scheme once the MA is approved. There is 
no need for an economic assessment for generic medicines as the price is much lower than the 
original medicine.  
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3. Generic medicines and the institutional framework  
The European medicine agency defines a generic medicine as: a medicine that is developed to 
be the same as a so-called reference medicine, which has already been authorized. Further, a 
generic medicine must contain the same active substance and doses to treat the same diseases 
as the reference medicine.  However, the difference from the reference medicine can be the 
name, inactive ingredients, appearance and packaging of the generic medicine. Generic 
medicines have the same manufacturing quality standards as all other medicines. They can 
first be developed for the market after the period of exclusivity on the reference medicine has 
expired (European Medicine Agency, 2013). 
 
In Norway, the Pharmacies Act was introduced in 2001 which regulates automatic 
substitution between original and generic drugs when dispensing pharmaceuticals in 
pharmacies. Usage of generic products is of great economic interest for payers, in this case 
the Norwegian health insurance scheme. Approximately 2 billions NOK are saved per year 
using generic medicines in Norway, which 75% of these are saved by NIS and 25% by the 
patient (NoMAc). 
 
3.1. The stepped price system  
The stepped price system model (Trinnprismodellen) is a scheme that ensures price fall in 
pharmaceuticals stepwise by predefined rates. The model was introduced in January 2005 to 
reduce the costs of National Insurance Scheme and it applies only after generic competition is 
introduced. The step price model applies for all active substances with generic competition, 
with the exception of some substances where it is not convenient to include in the model. 
Initially when the scheme began, 21 substances were included in the system. The system has 
now expanded with more substances since then (MOH b, 2013). 
 
The stepped price is determined when the first generic product enters the market. The stepped 
price is a percentage of the maximum price of the original drug at the time. The first price fall 
occurs as soon as the generic enters the market and is 30%. The second price fall occurs after 
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6 months and depends on the size of the turnover of the active substance before generic 
competition occurred. In addition there might be a third price fall 12 months after the second 
price fall if the appropriate active ingredient is sold for more than 15 or 30 million NOK 
(NoMAc).  
 
The diagram below describes how the stepped price system is applied: 
 
Figure 3.1. Stepped price system in Norway. Source by NoMA  
 
In order for generic pharmaceuticals to enter the market, the producers of generics have to 
come to a selling agreement with the wholesalers. When an original product has almost 
reached the end of its patent period, its generic products can start the process of entering the 
market. Firstly, the firms with a generic product must have MA and a set price, as well as be 
eligible for reimbursement. Secondly, the firms must send their offer to wholesalers where 
they present their price and conditions, and the negotiations start. The best offer is chosen, 
and the wholesalers make an agreement with the generic firm usually for a one-year period. It 
is very important for the generic firms to get the agreement first. This will give them an 
advantage in the market, as the consumer or patient will be familiar with their product. In the 
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future when more generics will enter the market it will be easy for consumers to choose the 
product they are familiar with (Subtracted from the conducted interviews). 
 
Once the generic product enters the market, the pharmacies are obliged to sell the cheapest 
product at stepped price, because that is the price that is being reimbursed by the government 
(St. meld. nr. 18 (2004)). If the patient would like to use the original product which is usually 
the expensive one, then he/she will have to pay the difference in the price i.e. if a generic 
product costs 70 NOK, and the original 100 NOK, the pharmacies have to offer the patient the 
cheapest one, regardless of which product the doctor prescribed. The patient then has a choice 
to accept a 70 NOK product or go for the original product, which costs 100 NOK. The patient 
would then have to pay 30 NOK from out of pocket.  
 
3.1.1. Inclusion of pharmaceuticals in stepped price system  
The Pharmaceutical Act, paragraph 12-15 determines the routines of inclusion of new 
substances in the stepped price system (NoMAd, 2013). All substances in the stepped price 
system have the following in common:  
1. The drug is in the substitution list. 
2. The original drug has stable generic competition from at least one drug in the 
Norwegian market.  
 
Before NoMA notifies the wholesalers of the inclusion in the stepped price system for a 
substance, a closer examination of the case of the generic is performed by:  
· Checking the Farmastat statistics if there have been registered generic sales.  
· Generic companies confirm in written form they are ready to deliver the generic 
product when contacted. - There have been situations in the past where generic 
companies were ready to deliver but the wholesalers chose to continue the agreement 
with the original company. This meant they continued to sell the original product at 
the stepped price level from the moment the generic companies were ready to deliver. 
Therefore the stepped price system model starts with the original drug excluding 
generic competition. According to the Pharmaceutical Act, if a generic is on the 
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substitution list and is ready to be delivered, it is sufficient for the stepped price 
system to be implemented (NoMAd, 2013). 
 
Furthermore, in some cases the applicable stepped price for a generic is too low and as a 
result it is not profitable to sell in Norway. In these cases NoMA has the authority to set a 
subjective price for the generic. This authority is based on the Pharmaceutical Act (NoMAd, 
2013). 
 
Once NoMA has established that a generic is selling in the market or the generic company has 
informed NoMA that it is ready to sell, the notification process begins. The process is 
summarised below:  
1. Pharmaceutical suppliers (both original and generic) get a notification via e-mail. 
They get 14 days to respond and comment on the notification.  
2. The reference group for stepped price, wholesalers and MOH are included as copy 
receivers of the e-mail. They can also respond and comment on the email within 14 
days.   
3. Comments are received by e-mail or letter. 
4. NoMA considers the responses and undertakes further decisions that are sent to 
suppliers by e-mail, including the stepped price reference group, wholesalers and 
MOH.  
5. The prices are sent to Farmalogg. The new stepped price enters the market on the 1st 
or 15th of the next month (NoMAd, 2013).  
 
3.2. The substitution list (Byttelisten)  
A medicine enters the substitution list scheme only if it is bioequivalent, medically equal and 
suitable for safe substitution in the pharmacies. NoMA ensures this in Norway.  
Two medicines are bioequivalent when their bioavailability is equal to the effect and security 
as a whole. This is determined by the studies that are carried out based on the common 
European guidelines. These studies confirm whether the body equally absorbs the active 
substance from both the original and the generic medicines (NoMAe, 2013).  
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Two medicines are substituted when they:  
· Contain the same active substance in dosage and strength. Only medicines with the 
same strength are automatically interchangeable in pharmacies.  
· Have the same medical form (capsules and tablet with fast substantial release are 
considered equal). 
· Have the same package size (+/- 20%). The pharmacy has to deliver enough 
medicines to a patient to ensure the treatment plan. In case of delivering a larger size 
than subscribed from the doctor, the pharmacies have to inform the patient not to use 
the leftovers of the medicines (NoMAe, 2013). 
 
An interdisciplinary group (Byttegruppen) using adequate guidelines decides if a medicine is 
equal and interchangeable, then passes their recommendations to managers at NoMA. The 
process is elaborated in several group meetings. This happens after a medicine obtains market 
authorization and price. The interdisciplinary group consists of pharmaceutical, medical, 
regulatory and jurisdiction competence. Certain types of pharmaceutical products are 
consumed in a unique way and as such cannot be automatically substituted with other 
products. These cases are sent to a hearing to determine whether the product is suitable to 
enter the substitution list or not (NoMAe, 2013).     
 
 
 
18 
 
4.Motivation and policy relevance of the thesis 
 
Martin Hoyle (2008) argues in the following article “Future drug prices and cost-effectiveness 
analyses” that most of the drugs were more cost-effective than the National Institute for 
Health and Clinical Excellence (NICE) stated. Hoyle calculated the real-price change of 373 
drugs in the UK between 1980-2006. Based on calculations the historic mean of the real-price 
change, across the drug products launched after 1984 with more than 500 prescriptions per 
year, his findings suggested that a future real-price of a drug should have a decreasing rate of 
4% per annum. However, when a drug patent is expected to expire in the near future, a 
generic drug will enter the market and the cost-effectiveness analyses should include the best-
estimated price decline of the generic (Hoyle, 2008).   
 
The Norwegian Ministry of Finance in its public report about socio-economic 
(samfunnsøkonomiske) analysis discusses the real-price adjustment of a good or service 
(realprisjustering) in chapter 4 (NOU 2012:16, 2012). A real-price adjustment is an 
adjustment of a calculated price that might grow in a different direction from the consumption 
price index. In order to compile the future benefit and cost of a project, one should make 
assumptions about how estimated prices will evolve differently during the period of the 
analysis. For the sake of simplicity the prices are usually kept constant. If the prices of a good 
or service rise relatively to the other goods or services during the analysis period, then the 
project appears less beneficial then it really is (NOU 2012:16, 2012). 
 
4.1 Why include the time spans in this thesis?  
The importance of the time span when evaluating cost effectiveness is stated by guidelines 
when NoMA reimburses the medicines.  
The Norwegian Health Directorate prepared a guide of health economic evaluation in which 
the time horizon of a health care programme is discussed.  
When calculating cost effectiveness in cases where there is a comparison between two or 
more health care programme alternatives, the time horizon of the programme outcome can 
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affect the cost-effectiveness. Therefore the time horizon should be long enough to capture the 
important differences between the alternatives, in cost and health effects. A programme can 
be of short duration, one or two years, but still have lifelong perspective consequences. A 
lifelong perspective is always suggested when a programme affects the life expectancies and 
the quality of life of the remaining life years (Norwegian Directorate of Health b, 2012).  
  
In order to make a better assessment in price paths for pharmaceuticals, it is important to be 
aware of the factors that affect the price path. Therefore an estimation of time span used for 
generics to enter the market from the time they apply for MA is of important value when 
issuing reimbursement for pharmaceuticals.  
 
This paper is based on Hoyle’s findings and the requirement from the Ministry of Finance 
about the real-price for services in Norway. 
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5. Methodology  
 
5.1. Study design 
The focus of this thesis will be to study the process of a generic pharmaceutical entering the 
market in Norway. The study will also consider and estimate how long it takes for 
pharmaceutical companies to obtain Market Authorisation and also how long it takes for the 
stepped price system to be established.  
 
To obtain the required information for the study, relevant data was collected from the 
NoMAs’ database on each substance in the stepped price system in Norway from 2005 to 
2012 and the range and median was determined for each time span. In addition, further 
information was collected in an attempt to find answers to the question of why generics used 
a particular time span to enter the market.   
 
To ascertain a more accurate and complete investigation a combination of quantitative and 
qualitative research approach was used and the single case study design was chosen to gain 
insight and a better understanding of the process. The reference period of the study is 
retrospective since the investigation is based on the existing data from the period May 2005 to 
December 2012 (Kumar, 2001).  
 
A research approach is classified as quantitative if the purpose of the study is to quantify the 
variation in a situation or phenomenon, and if the analysis is adapted in order to match the 
magnitude of the variation (Kumar, 2001). This research approach was employed and 
presented through the systematic data collection at NoMA for this thesis.  
 
Furthermore, a combination of quantitative and qualitative research approach was used. 
Quantitative research approach is used, according to R Kumar when “you want to quantify the 
variation in a phenomenon, situation, problem or issue; if information is gathered using 
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predominantly quantitative variables” (Kumar, 2001:13). Quantitative data is used to find the 
time span of four phases in-between, from when the original drug entered the market until the 
generic competition was established and statistical tests are performed to find and present the 
different findings of the four phases. A research approach is classified as qualitative if the aim 
of the study is to describe a situation or phenomenon where the analysis is done to establish 
the variation without quantifying it (Kumar, 2001). The qualitative research approach was 
appropriate to use in this thesis in order to describe the expert views of the system through a 
single case study.  
 
Based on R Kumar’s book, the objectives set define the type of research for this thesis as a 
combination of both descriptive and exploratory study. This thesis is a descriptive study, as it 
is an attempt to systematically describe an existing situation or phenomenon and provide 
insights about potential issues (Kumar, 2001). The study has an exploratory approach as 
defined by R Kumar  “a study where objectives are to explore in an area where little is 
known” (Kumar, 2001:10).  
 
A single case study is used in both qualitative and quantitative studies for an exploration of 
the in-depth and general aspects of what the researcher wants to find out. Moreover, a single 
case study design is useful when little is known and the researcher wants to gain a holistic 
understanding of the situation or phenomenon (Kumar, 2001). This study design is 
appropriate for this thesis, since I am the first to gather the data systematically from NoMA 
and in order to provide insightful findings in the current situation of the time span used by 
generics before entering the market.  
 
In order to reach the set objectives, gathering of more information on the process was 
necessary. Oral history method data collection seemed suitable. I decided to obtain this data 
by gathering information from professionals working with generic drugs and addressing a 
variety of questions about their experiences with generic competition and the stepped price 
system. Oral History method of data collection enables the researcher to study experiences 
and gather the historical knowledge of an event, as viewed by individuals. This process 
involves the identification of the type of experience or historical event the researcher wants to 
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find out and the identification of individuals who are able to give her/him best information 
needed (Kumar, 2001).   
 
In order to collect the data through oral histories, in-depth and semi-structured interviews 
were conducted with professionals in the field. The decision of using semi-structured 
interviews was made to give the informant the freedom to speak within the topic of the thesis.  
 
5.2 Hypothesis difficulties 
In the beginning of the process of writing this thesis several hypothesis ideas were tried in 
order to capture all the questions attempted to answer in this thesis. Furthermore, it was 
attempted to generalize the results of the elapsed time span used to enter the market for all 
generics. However the qualitative data was limited and skewed, and covered only one part of 
the thesis. Later on, it proved to be difficult to choose a hypothesis that covered all the issues, 
as the pharmaceutical system is quite complex and many aspects affect it.  
 
The thesis was designed to describe the data and dividing them into phases, thereafter each 
phase into two time periods from 2005-08 and 2009-12, in order to determine if there was any 
difference in the process between the two periods. The process here refers to the time used for 
generics to receive MA and the time used for generics to enter the market after receiving MA. 
Another important part of the thesis was the information conceived by the interviews, which 
fulfilled the quantitative results.  
 
5.3. Quantitative data selection 
The data selection included only out-patient drugs with generic competition which are part of 
the stepped price system. The data was collected manually from the database Athene and 
P360 at NoMA. It includes all the substances based on the Anatomic Therapeutic Chemical 
(ATC) codes in the market, which have generic competition and have entered the stepped 
price system from May-2005 until December-2012 (Appendix I). The World Health 
Organization (WHO) uses the ATC code system as a classification system for drugs. The aim 
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is to improve drug use, with the help of the ATC system, by using it as a tool for presenting 
drug utilization statistics (WHOCC, 2011). For each substance it was required to go back in 
time and collect the time spans used from when the original received MA until the generic of 
the substance entered the market.  
 
Each original pharmaceutical can have more than one generic competition in the market, 
therefore the dataset was narrowed down by only including the first generic that entered the 
market and influenced the price to decline initially. The table below shows an example of a 
substance called Terbinafine. There were four generics in the market for this substance but 
only the one from Ratiopharm GmbH was included in the dataset of this paper because it was 
the first generic to enter the market.    
ATC-Code Substance Generics entered the 
market 
Date of market entry 
D01BA02 Terbinafine Actavis Group 01-08-05 
  Hexal 01-06-06 
  Orifarm Generics 01-01-06 
  Ratiopharm GmbH 01-05-05 
Table 5.1. Selection of the generic firm for the data set  
For some cases it was difficult to find the accurate dates, as they were not registered in the 
Athene system. In such cases, the dates were extracted from the initial application form that 
was sent by the particular firm to NoMA. 
 
The data was collected chronologically from May 2005 until December 2012. Further the 
dataset was divided into 4 phases of the process, described below:  
1. From the date the originator received market authorization until the date the original 
entered the market. 
2. From the date the generic applied for market authorization until the date it received 
market authorisation. 
3. From the date the generic received market authorisation until the date the generic 
entered the market 
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4. From the date the original entered the market until the date the generic entered the 
market.  
The phases are represented in days, they were calculated by dividing the most recent date 
minus the previous date in the dataset i.e. phase one = the date the original entered the market 
minus the date the original received MA. The main interest of this paper was in phase two and 
three.  
 
The descriptive statistics of the dataset collected showed the data was skewed and therefore it 
was not suitable to perform a T test using the mean as a comparator. Instead the Man Whitney 
U Test was performed as it uses the median comparator and is more suitable to compare the 
two periods in question, namely from 2005-08 and 2009-12. These periods were chosen 
because the amount of the data was satisfactory in each of them. After each phase was divided 
into two periods the Mann Whitney U Test was used to compare if there was any change in 
the time spans of each phase.  
 
Mann-Whitney U test is nonparametric test and utilized when two independent random 
samples are taken from two populations. The assumptions are: the two population 
distributions are identical and have the same central location, called the median (Newbold, 
Carlson, Thorne, 2007). It is equivalent to T test, but Mann-Whitney U test is used when the 
assumptions of the T test are not met and when the data are ordinal. (Hilton, Brownlow, 
McMurray, Cozens, 2004). 
 
The Man Whitney U test ranks the data in a scale from the lowest to the highest and compares 
the ranks between the two given groups. The Man Whitney U test calculates two U values in 
the two populations and provides us with statistics that allows us to decide when we can claim 
a difference between the samples. If both U values are the same it means the population 
samples are very mixed amongst the ranks and there is no difference between them. However 
if one U value is larger and the other value is smaller then it indicates a separation of the 
groups amongst the ranks.  
25 
 
“To test the significance of our difference we take the smaller of the two U values and 
examine the probability of getting this value when there is no difference between the groups. 
If this probability is lower than our significance level (p-value smaller than 0.05) we can 
reject the null hypothesis and claim a significant difference between our samples” (Hilton et 
al, 2004). 
 
In order to determine if the results were stable, another two slightly different periods were 
chosen from the dataset, namely 2005-09 and 2010-12. Then the Mann Whitney U test was 
performed again for these periods as well. The same concluding results were found between 
these two slightly different periods as well, which confirmed the initial results were stable.  
 
The statistical programme PASW Statistics (formerly SPSS) version 20 was used to perform 
statistical analysis such as Descriptive Statistics and the Non-parametric Mann Whitney U 
Test. Descriptive Statistics were performed for each of the phases mentioned above and box-
plots were produced to visualize the data distribution of the time span for each phase.  
 
5.4. Qualitative data selection  
In order to strengthen the findings of the 4 phases of the process, 12 interviews were 
conducted with relevant professionals in the field. Judgmental or purposive sampling was 
used to choose the participants. The decision was made thoughtfully with the help and 
recommendation from my contacts at NoMA, based on the judgment of who can provide the 
best information, so the objectives of the study can be met. The participants were people who 
had the required information and were willing to share it with me. This type of sampling 
method was appropriate for my study because the aim is to describe and develop information 
in areas where gaps remain and little is known (Kumar, 2001).   
 
The goal was to reach the right informants in the field, therefore a list of many individuals 
who have knowledge about the topic was compiled. It was soon evident that interviewing a 
lot of professionals was essential, as the process of entering the market consists of many sub-
processes linked together. Furthermore, I included representatives from each sub-process and 
26 
 
eliminated informants with similar background in order to narrow down the sample data. The 
sub-groups consisted of: 
· Original and Generic pharmaceutical firms  
· People working with the market authorization process, reimbursement and price 
setting of pharmaceuticals at NoMA  
· Wholesalers and interest organization for pharmaceuticals in Norway.  
 
All participants informed me about their part of the process and in addition they also included 
information about other sub-processes in context.   
 
All informants were recruited by e-mail correspondence. Along with the invitation, an 
information letter was sent (Appendix II). The letter comprised information about the project 
and the importance of its conduction, as well as information about the procedure of the 
interview along with the participant’s rights. Initially, 14 informants were contacted and two 
declined. The overall response to participate in the project was positive, there were only two 
participants who needed more information about the project before they agreed to participate. 
Interviews were conducted from December 2012 to February 2013.   
 
5.4.1. The interview  
For the purpose of this thesis the semi-structured interview was used to obtain the data, as the 
main objective was to gain in-depth information about the process of generics entering the 
market. A semi-structured interview implies a mixture of structured and unstructured style of 
interview based on their flexibility, according to R Kumar. The unstructured interviews give 
the interviewer a complete freedom in structure and content, as well as formulating questions 
spontaneously according to the context of the discussion. The structured interviews are 
described as rigid in structure and contents, while the questions are set predominately and 
asked in the same wording and order as specified in the interview schedule (Kumar, 2001).  
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A covering letter with the main questions was sent to each participant as suggested by R 
Kumar. All the interviews were conducted face to face and with one informant at a time. A set 
of questions was prepared in advance, in order to steer the informant back to the topic in case 
they deviated away from the main topic. A recording device was used, as well as notes were 
taken during the interview. The covering letter is presented in appendix II.   
 
5.5. Ethical issues  
Ethical considerations are important when conducting research. An application form for a 
permition to conduct the interviews was sent to Norwegian Social Science Data Services 
(NSD). NSD did not consider the project as very personal because the questions the project 
addressed were not personal and did not represent a threat for the participants’ personal life or 
their workplace.  
 
5.5.1. Seeking consent  
Collecting information without the knowledge, expressed willingness and without the 
informed consent of participants is considered unethical. According to R Kumar informed 
consent implies that subjects are made adequately aware of the type of information you want 
from them, why the information is being sought, what purpose it will be put to, how they are 
expected to participate in the study, and how it will directly or indirectly affect them (Kumar, 
2001). 
 
As previously mentioned, a covering letter with information about the purpose and the 
importance of the project was sent along with the invitation to participate in the study. It was 
noted that the participation is voluntarily and that they could withdraw their consent at any 
time of the study. In cases where the participants were to be quoted, they were asked for their 
consent beforehand. In addition to the covering letter, the same information was given 
verbally before each interview and the informed consent was collected verbally.  
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5.5.2. Confidentiality 
Maintaining confidentiality is another important aspect in research when accumulating data. It 
implies that a researcher should ensure the source of information and the identification of an 
individual respondent, is kept anonymous at all times (Kumar, 2001).  
 
Confidentiality in this paper is assured to the best possible ability and the source of 
information is kept anonymous at all times. During the recruiting process the participant was 
contacted individually via e-mails in order to protect her or his anonymity. I made sure I was 
the only person who listened to the audio recordings of the interviews and the transcriptions 
were read only by me. During interviewing there was no disclosure of other participants of the 
same interview. My connection at NoMA is aware of most of my informants since the list of 
the participants was made in collaboration with her, although she does not have any 
information about the response. Despite this fact, it is not considered this caused any bias for 
the paper.  
 
5.5.3. Avoiding bias 
According to R Kumar, introducing bias into a research activity is also unethical. He defines 
bias as a deliberate attempt to either hide what you have found in your study, or to highlight 
something disproportionally to its true existence. Bias differs from subjectivity, as 
subjectivity is an integral part of the researcher’s way of thinking and is conditioned by e.g. 
educational background, training, competence, philosophical perspective etc. (Kumar, 2001). 
 
The risk of introducing bias has been considered throughout the process of writing this thesis. 
The presentation of the results had special attention as an attempt to maintain objectivity. In 
some cases a recommendation of other potential participants was mentioned from the 
interview participants. However, it was not considered as important and was often declined in 
a polite way, besides the number of informants had already been covered. This thesis was 
requested by NoMA but there was never an attempt to influence the results of this paper in 
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any circumstances. Moreover, the information collected by participants was often to some 
extent similar. This made it easier to present the results objectively.   
  
5.6. Validity and reliability  
 
5.6.1. Validity  
Validity in the research process intends to answer the question: Are we measuring what we 
aim to measure in accordance with the project’s objectives? (Kumar, 2001). Moreover, R 
Kumar divides the establishment of validity into two approaches; the logical and statistical 
evidence approach. The statistical evidence approach implies the use of procedures that 
provide evidence through calculations of the coefficient of correlations between the question 
and the outcome variable (Kumar, 2001). The logical approach is when a link is established 
between each question and the objectives. Establishing the validity of tangible concepts such 
as age or weight is less difficult than for less tangible concepts like satisfaction, effectiveness 
or attitude. A wide variation of questions should be asked in order to capture several aspects 
of the concept, as well as demonstrate that the questions asked are measuring what they intend 
to measure (Kumar, 2001).   
 
Based on the amount of interviews used to collect information about this thesis, the internal 
validity was established. R Kumar explains internal validity as credibility in research (Kumar, 
2001). All participants included in the interview process represented every part of the 
pharmaceutical market. Questions used to obtain answers towards the objectives of the study 
provided insights, as well as the participants´ view of the process. Narrowing the amount of 
participants to 12 was considered appropriate since all parts of the market were covered. 
Certainly, the possibility to interview more representatives was there but it was time 
consuming and not considered as necessary.   
 
The external validity or transferability is obtained when the research results can be 
generalized to other research (Kumar, 2001). Considering the external validity some of the 
results of this thesis might be transferable in other settings, whereas some of the results might 
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not due to the special pharmaceutical system used in Norway and personal opinions of the 
participants.  
 
5.6.2. Reliability  
A research tool is reliable if it is consistent and stable; this implies that the research tool is 
predictable and accurate. If a test or scale produces the same results when it is undertaken 
several times, under the same circumstances and with the same instrument it is said to be 
reliable (Kumar, 2001). In social science it is impossible to control the factors affecting 
reliability like:  
a) The wording of questions – the reliability can be affected if there is a use of ambiguous 
wording in the questions. This might result in different responses at different times. 
b) The physical setting – change in physical setting might result in different responses given 
by the participant.  
c) The mood of the participant and the interviewer – the mood could change from time to time 
and from interview to interview. This might affect the reliability of the interview.  
  
During the process of creating this thesis a special attention was paid to the formulation of the 
questions used in the interview. 
 
5.7. Limitations 
While writing this thesis, there were certain limitations that I faced which the reader should 
consider when reading the results and conclusions of this thesis. 
 
The first limitation met during the process of producing this thesis was the lack and of 
literature describing why generic firms used the time span they did before entering the market 
in Norway. The only literature found was the description of the pharmaceutical system in 
Norway. Therefore, all the reasons and arguments outlined in the qualitative results section 
are produced from the information extracted from the interviews conducted.  
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An attempt not to be influenced by the participants in the direction of their interests or cause 
has been highly prioritised to maintain an objective perspective. This was done by being alert 
during and after the interviews, so I could filter out information considered as promotions of 
the informant’s own causes. 
 
Another limitation was the small sample of data available from NoMA. It is hoped that this 
work will stimulate further research in the field when several additional substances are 
available in the market, to provide en even more up-to-date picture. 
 
Finding an explicit theoretical framework for the thesis approved to be challenging. 
Unfortunately, a definite theory to account for the thesis in its whole has not been formulated 
for the Norwegian market. Attempts to find an applicable theory have been made, however 
each theory considered complemented parts of the thesis. Some of the theoretical frameworks 
taken into account were the Price Theory for setting the price of generics, and the Market 
Theory describing the process of the market authorisation. Nevertheless, these theoretical 
frameworks did not entirely cover the main topic of the thesis.  
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6. Results  
In this chapter the four phases will be represented with their corresponding results from both 
statistical analysis and interview findings.  
 
6.1. Quantitative results  
6.1.1. Descriptive statistics  
Descriptive statistics of the dataset show the distribution and the time span used in each phase 
in the table below. The table 1 illustrates that the data is skewed and the variance within each 
phase is quite high. A detailed description will be given below, in the result chapter of each 
phase (Section 6.1.2 -6.1.4).   
 
 N Minimum Maximum Mean Std. 
Deviation 
Variance Skeweness 
Statistic Statistic Statistic Statistic Statistic Statistic Statistic Std. 
Error 
Phase 
One 
53 9 605 133,94 138,589 19206,978 1,819 ,327 
Phase 
two 
52 0 1080 390,56 238,133 56707,467 ,885 ,330 
Phase 
tree 
53 0 3414 293,83 526,249 276937,832 4,545 ,330 
Phase 
four 
52 1005 10834 4039,55 1697,701 2882188,829 1,881 ,327 
Valid 
(listwise) 
52        
Table 6.1. Descriptive statistics for all four phases, the variable represent number of days.  
It was anticipated that there would be difference in the amount of days used within each 
phase. This formed the basis to employ the Mann Whitney U test for this paper. The Mann 
Whitney U test compares the dataset between two periods 2005-08 and 2009-12. The last 
phase, phase four in the table 6.1, overlaps with the first three phases as it is a sum of all 
phases.  
 
Further a box-plot is shown for each phase to illustrate the data visually. Normally, the black 
line in the centre of a box-plot represents the median value of the dataset. Half of the data 
falls in the shaded box and it should be between 25% and 75% of the data spectrum. The lines 
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extending from the shaded box connect the highest and the lowest data points that are not 
considered to be outliers. These data points are referred to as whiskers.  Data points larger 
than 1.5 times the box-length, falling outside the 25% and 75% range, are outliers and   are 
depicted in the figures by circles. Extreme values are data points that are 3 times larger than 
the box-length, indicated in the figures with a star. These data points are not considered as 
falling inside the range of points to be displayed in the distribution. Outliers might indicate an 
error in the dataset (Hilton et al, 2004).   
 
6.1.2. Phase one: From the date the originator received market authorization until the 
date the originator entered the market 
Phase one is defined as the days used from the time point the originator received MA until 
they entered the market.  Phase one was introduced for comparison of the time spans used in 
this phase with those in phase two and three.  
 
  
N 
 
Mean 
 
St.dev. 
 
Min 
 
Max 
Percentiles 
25th 50(median) 75th 
Phase one 53 133.94 138.58 9 605 42.50 86 196 
Table 6.2. Descriptive statistics for phase one 
The Original firms used in average 133 days, from receiving MA until they enter the market. 
The median, which represents the middle observation of the dataset when arranged in 
increasing order, is 86,00 days.  The explanation for this short usage of time might be due to 
the patent the originator possesses and the lacking of competitors in the market (Brekke et al, 
2007).  
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Figure 6.1. Box-plot for phase one.  
Box-plot in the figure above illustrates the concentration of the data in the lower part of the 
box  including 3 outliers. The upper whisker is wider than the lower one and the median line 
is in the lower part of the shaded box, implying a clearly skewed dataset. The dataset contains 
large outliers, which results in a greater mean than median, indicating that the data is 
positively skewed (Newbold et al, 2007). 
 
The Mann Whitney U test of this phase compares the time spans between two periods 2005-
08 and 2009-12. The two periods are compared in order to determine whether the original 
firms used longer or shorter time spans to enter the market after receiving MA. 
 Entered SPS N Mean Rank Sum of Ranks Mann- Whitney U  p-value Phase one  2005-2008  2009-2012    Total         23 30 53 26.30 27.52 605 826 329 0.774 
Table 6.3. Ranks and test statistics for phase one 
As expected for this phase there was not a statistically significant difference between the two 
periods (2005-08 and 2009-12), the p-value is 0.774, it exceeds the 0,05 p-value ceiling. In 
addition the mean ranks are close to each other with the values of 26,3 and 27,53.  This 
reflects the reality of Original firms where they can enter the market without any obstacles, as 
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well as their interest in entering the market as soon as possible. Normally, original firms 
operate quickly after they receive MA.  
 
 
Figure 6.2: Box-plot for the two periods in phase one.  
The box plot shows the median in each period is very similar even though the distribution of 
the data is different, suggesting that the null hypothesis is not rejected. The second period has 
several more outliers and the data from the 25th percentile and 75th percentile is further 
concentrated. 
 
6.1.3. Phase two: From the date the generic applied for market authorization until the 
date it received market authorisation  
The data is positively skewed in phase two as well because the mean is greater than the 
median. The mean is 390,56 days and the median is 357,00 days from when the generic 
applied for MA until they received MA as shown in table 6.4 below. 
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N 
 
Mean 
 
St.dev. 
 
Min 
 
Max 
Percentiles 
25th 50(median) 75th 
Phase two 52 390.56 238.13 0 1080 202.25 357 534.75 
Table 6.4. Descriptive statistics for phase two  
 
As explained in Section 2.4. Market Authorization, the process of getting MA exceeds the 
210 days when we measure the total days used between applying and receiving MA.   
 
 
Figure 6.3. Box-plot of the phase two  
The figure above shows that the majority of the data is concentrated in the middle however 
the data is moderately. There are two outliers presented in this dataset.    
 Entered SPS N Mean Rank Sum of Ranks Mann- Whitney U  p-value Phase two 2005-2008  2009-2012    Total         23 29 52 18.41 32.91 423.50 954.50  147.50 0.001 
Table 6.5. Ranks and test statistics for phase two 
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The Man Whitney U test shows that there is a statistically significant difference between the 
two periods of 2005-08 and 2009-12 for Phase Two with a p= 0.001. In the period 2009-12 it 
took longer time to acquire MA approval than in the previous period of 2005-08 (Table 6.5). 
It took longer time to acquire MA approval during 2009-12 than it did in the previous period 
of 2005-08. 
 
   
Figure 6.4. Box-plot of Phase Two for both periods 
The box-plot illustrates a clear difference of the two periods in this phase. In the first period 
2005-08 generics received MA much quicker than in period 2008-12. The difference of the 
median is wide, implying that the null hypothesis is rejected.  
 
6.1.4. Phase three: From the date the generic received market authorisation until the 
date the generic entered the market 
 
In phase three there are several steps required, from all parts of the system, before the generic 
can enter the market and the stepped price system.  Upon deciding to enter the Norwegian 
market, the firm is required to apply for a selling price of the product and apply to enter the 
substitution list (PHIS Pharma Profile Norway, 2011; NoMAe, 2013). When this is in order 
the firm needs to obtain a contract with wholesalers in order to be able to sell the product. The 
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generic firm is often ready with a finished product while waiting for the patent of the Original 
drug to expire. The difficulties faced in each of these requirements are elaborated in the 
qualitative part below in sections 6.2.2 to 6.2.6.  
 
The Descriptive statistics illustrate a great difference between the mean of 293,83 and median 
of 131. The Standard Deviation is also high. The below calculations indicate that there is a 
highly skewed dataset.  
 
  
N 
 
Mean 
 
St.dev. 
 
Min 
 
Max 
Percentiles 
25th 50(median) 75th 
Phase 
three 
52 293.83 526.24 0 3416 63.25 131 277.25 
Table 6.8.Descriptive statistics for phase three  
 
 
Figure 6.5. Box-plot of the data for phase three 
 
In the figure above the box-plot of the third phase is depicted, extreme outliers as well as a 
broad variation between days used for each substance are observed. The minimum number of 
days from the time the generic received MA until they entered the market is 0 days. This is 
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because some of the substances do not have generic competition that already entered the 
market. The reason being, the firm producing the original drug choose to decrease the price 
and enter the stepped price system themselves. In addition, there are several outliers in this 
phase, for some substances it took a long time to enter the market after approved MA, i.e. for 
one of the substances it took 3416 days (Appendix 1). This might have occurred due to a 
court trial and patent violation, more details about patent violations are explained below in 
qualitative results in section 6.2.2. 
 Entered SPS N Mean Rank Sum of Ranks Mann- Whitney U  p-value Phase three  2005-2008  2009-2012    Total         23 29 52 18.43 32.90 18.43 32.90  148.00 0.001 
Table 6.9. Ranks and test statistics for phase three 
The Mann Whitney U test shows a statistical significance between the two periods with a p= 
0,001. In the second period the generic firms used more time to enter the market after 
approved MA.  
 
 
Figure 6.6. Box-plot of phase three for both periods  
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The box-plot illustrates the skewed distribution of the data in the two periods. The arguments 
to why there is a variation in the data between the two periods are commented in sections 
6.2.2. to 6.2.6.   
  
5.1.5. Phase four: From the date the original drug entered the market until the date 
the generic competition started 5.1.6.  
Phase four is included to summarize and establish the time span of all the three previous 
phases in the dataset of this paper. As expected it took 4039 days on average for the 53 
substances, approximately 11 years to get generic competition from the date the original 
entered the market. The median is 39 days smaller than the mean. Therefore the dataset is 
considered to be positively skewed.   
 
  
N 
 
Mean 
 
St.dev. 
 
Min 
 
Max 
Percentiles 
25th 50(median) 75th 
Phase four 53 4039.55 1697.70 1005 10834 2937 4000 4641 
Table 6.11. Descriptive statistics for phase four 
  
 
Figure 6.7. Box-plot for phase four 
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The box plot above shows how the data is distributed from the time point the original entered 
the market until when the generic entered the market. The median is in the upper part of the 
shaded box, implying that the data is skewed. There are 3 outliers in the box-plot; these 
outliers used a long time to enter the market. Some of the outcomes from   phase two and 
three might have an impact on phase four.  
 Entered SPS N Mean Rank Sum of Ranks Mann- Whitney U  p-value Phase four  2005-2008  2009-2012    Total         23 30 53 26.96 27.03 620 811  344 0.986 
Table 6.12.Ranks and test statistics for phase four 
The Mann Whitney U test shows no statistical significance, with the p=0.986 between the 
periods 2005-08 and 2009-12 of the phase four, there is no indication in difference in the time 
span used between substances. The hypothesis that there might be a difference in the time 
spans between the two periods is not true. So the null hypothesis is not rejected. 
 
6.2. Qualitative results  
In this part of the thesis an attempt was made to find out why it took so long time for some 
generics to enter the market. Why did generic products use longer time to enter the market in 
the second period? When does a generic firm start the process of entering the market?  
 
6.2.1. The obstacles during the MA process    
One of the inquires of this paper was to examine the reason for using a clock-stop during the 
MA process. The answers received from informants suggested the clock-stop is there to cover 
unanticipated events in the MA process due to variations from one product to another. In 
some cases the EMA cannot come to an agreement internally between member states and 
requires more information about the pharmaceutical, chemical or bio-similarity. Other reasons 
can be requirements to improve the wording and the appropriate translation of the information 
in the Norwegian language. In some cases the firm does not send the translated version to 
NoMA, regardless of this NoMA might release the MA,  however, the firm is not allowed to 
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start selling before the translation is in place. Potentially, the name of the drug may be 
inappropriate, so the firm is required to find another one. This process of arguments back and 
forth can sometimes turn into a long discussion. The generic firms reported that sometimes it 
was time consuming to gather the required documentation for MA.  
 
The informants from both the original and generic firms, as well as from NoMA reported that 
when applying for MA the Centralised Procedure was mostly used. It is more convenient for 
the firms to go through the Centralised Procedure because when MA is granted it can be 
utilized in all member states.  
 
All the informants from NoMA and from the firms reported there was a queue in processing 
the MA application because of the lack of the capacity at NoMA. The 210-day application 
process exceeded and it was reported that the queue went up to 3 years for a MA process to 
complete. Therefore in 2008 NoMA changed this by employing more workers, which resulted 
in increased resource capacity for processing the application. Another 3 years were spent in 
order to eliminate the queue that had built up previously. Many of the substances in the 
dataset of this paper entered the market during the queue period. This situation could have 
potentially delayed the MA application process even further. After the queue at NoMA was 
eliminated, all the interviewed firms expressed their satisfaction with the processing of MA at 
NoMA. 
One participant from a firm stated: 
…but now there is no queue when applying MA and we are very satisfied with that. 
 
6.2.2. The Patent obstacles    
 
Generic firms have to wait for the patent of the originator to expire in order to enter the 
market. In the interviews conducted it was reported by all the informants that until recently in 
Norway, Pharmaceutical firms actually received a process patent when innovating a new 
product as opposed to a product patent. The Process patent protects the process of how the 
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drugs are produced and prepared, but it does not protect the product itself. There were cases 
where generic companies found new ways of producing the drug and entered the market 
before the patent of the Original drug expired. This situation gave rise to conflicts of interest 
and sometimes ended in a court trial. These court trials have extended the average time to 
complete the phase of entering the marked after getting MA. 
 
However, currently only the product patent is used on innovative products and soon there will 
be no original product with a process patent remaining in the market. The informants 
confirmed that it was easier to deal with product patents compared to the process patents. For 
example, a generic company would not be tempted to find another process of producing the 
drugs while at the same time an original company would not have to worry about losing it’s 
exclusivity in the market.  
 
Original pharmaceutical companies are interested to extend the patent duration and can 
sometimes complicate the patent time by possessing several patent types for the same drug; 
such as for substance, different dosage forms and other parts of the drug. To avoid patent 
violation the generic companies are obliged to try to find out about all the different patent 
types an Original drug might have, before they enter the market. There were cases where the 
patent was violated by a generic company and a court trial followed as the generic had missed 
a patent date. The generic companies claimed they were interested to avoid court trials and are 
careful when entering the market.  
 
Generic firms apply for MA long before the patent of Original expires so they can be ready to 
enter the market when the patent expires. This has an effect on the time it takes to complete 
the phase three - from approved MA until they enter the market. 
 
6.2.3. Norway is a small market 
While analysing the data it was observed that many generics had MA but they never entered 
the market. A possible explanation for this may be the firm possessed the MA in all member 
states but chose to sell in only some of the states. It should be noted that in some cases 
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generic companies might not enter the Norwegian market straight away after they receive 
MA, there could be business or other reasons for not doing so and therefore this introduces 
another delay to the process. One representative from the firms said:  
“Before we decide producing a generic we check to what extent  the original is sold, if it is an 
important drug with high profit we decide to compete with other generic firms in entering the 
Norwegian market”  
Another representative from the firms said:  
“Norway is a small country compared to Germany and UK, therefore not a priority for us to 
enter the market right away”   
6.2.4. Production issues of Generic Drugs  
 
Generic firms claimed that when attempting to produce a drug, firstly they have to establish 
the pharmaceutical development of the drug and also determine which production company 
should supply the chemicals required for the substance wished to be produce. In some cases, 
after starting the process of developing the drug, the original firm bought the chemical supply 
company that would provide the generic firm with the chemicals. One representative 
informed:  
“After we found a supplier for the chemicals we needed for the production and came to an 
agreement, an original producer bought the whole factory.” 
 This resulted in the delaying of the developing process for generic firms, as the generic firms 
have to find other supply companies that met their requirements before an actual business 
agreement.  
 
6.2.5. The substitution list and reimbursement schemes  
 
The generic drugs need to enter the Substitution List Scheme in order to be reimbursed by the 
Norwegian Health Insurance Scheme. Informants at NoMA claimed, when the first generic 
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product receives a price from NoMA, the Stepped Price System department starts to consider 
whether the drug can be a part of the Substitution List Scheme.  
 
The entrance in the Substitution List Scheme is not problematic in most cases. The effect of 
the drug has already been validated during the process of receiving MA. In addition to double 
checking the bio-similarity of the drug, the Substitution List Group considers whether the 
generic product is substitutable with the original product. The questions addressed to this 
process are:  Is it possible to take the generic product in addition to the original, if the patient 
might misunderstand, and what are the consequences of double dosage? Can the patient 
choose not to take the drug at all because they are afraid of the effects of the new drug? All 
these consequences are considered in both short and long term effects before the Substitution 
List Group agrees to reimburse the drug. The generic drug will enter the substitution list 
immediately if there are no other factors to be considered. If there is insecurity about the use 
of the drug in different patient groups, a wider discussion begins with all the parties involved 
including patients, doctors, specialists and patient organisations. In some cases before the 
decision is made, open hearing sessions are organized to get the opinion of all the parties 
involved. As a consequence the processing time for a generic product to enter the substitution 
list might exceed the 180 days limit by an additional 6 weeks or even up to 1 year more.  
 
6.2.6. Wholesalers and the Norwegian market 
 
All informants mentioned that they believe the wholesalers have a great power in the 
Norwegian pharmaceutical market. For a drug to enter the market an agreement contract 
between the pharmaceutical firm and the wholesaler needs to be completed. The wholesalers 
negotiate the purchase price with these firms. When a generic drug is ready to sell it enters the 
Stepped Price System. Original firms can also enter the Stepped Price System if they choose 
to compete with generic firms during the wholesaler’s negotiations on finding the most 
suitable drug. Both original and generic firms commented that the wholesalers have various 
strategies when selecting which product to buy. They might focus on a low price, which they 
can get from a generic firm, or they might focus on professional and quality profile, in which 
case they will prefer the original firm.  
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The generic producers interviewed explained sometimes when they possessed MA and were 
ready to launch, the wholesalers made an agreement with original producer even with a higher 
purchasing price and the stepped price was launched with original, but the generic never 
entered the market or was delayed for a long period of time. The generic production firms 
claimed that at this time of the process a lot of money had been invested and lost as a 
consequence of how the stepped price functioned. In the dataset presented this phenomenon 
was observed, but only twice. It seems that for now this appears rarely, however, it might 
reappear in the future. This is the reason why in the phase two and three, the time span starts 
from day 0, because there is no generic drug in the market and only the original entered the 
stepped price system after its patent expired.  
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5.2. Other findings 
  
The Stepped Price System cannot be established if the original drug does not have a 
competition i.e. a generic that is ready to enter the market. 
 
Both wholesalers and generic companies did complain about the pharmaceutical act where 
they are obliged to offer the drug at a stepped price, even if there are production problems 
with the drug and the pharmacy might not have the drug in stock. The wholesalers might only 
have the original drug in stock in which case they are obliged to offer the original drug at the 
stepped price, while incurring the cost themselves. This would be the case if NoMA notifies 
the entrance of stepped price before the wholesalers made an agreement with any production 
firm to sell the drug at stepped price. 
 
Pharmacies are obliged to sell the cheapest product in order for the government to reimburse 
them. They are obliged to deliver the medicine required by the patient at all times. As a 
consequence the wholesalers often make an extra agreement with the generic firm called 
Compensation Claim Agreement. They agree that if the generic firm cannot deliver the 
generic product to the wholesalers then they have to pay the full price of the original product. 
This means the generic firms will end up paying a much larger amount of money per 
medicine to the wholesaler if they don’t deliver, while protecting the patient from such costs. 
One participant said:  
 “This is one of the reasons that withdrew the producers away from the Norwegian market.”   
The selling agreement between the wholesaler and the production firm of the drug in the 
Stepped Price System often lasts one year. Therefore it is important for generic firms to be the 
first to enter the market after the original, so they can get well known among the patients and 
get the chance to sell their product. The pharmacies are obliged by law to offer the drug on 
stepped price either as a generic or original, once the stepped price is established.  
 
There are a lot of generics per substance with MA that never enter the Norwegian market. The 
informants gave several reasons for this, one of them was that the Norwegian market is small 
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and the second reason is the substance representing a small group of users and does not sell 
profitably. The generic firms are not interested because it is not profitable to enter the market. 
The third reason might be the way Norwegian market is regulated; it does not provide room to 
have several generics in the market at a time.   
 
6.4.  Summary of results 
In this paper it was discovered that in order for a generic medicine to obtain MA it takes on 
average 357 days (median), while a generic used 131 days according to median to enter the 
market after approved MA. During the interviews several reasons were identified for this time 
span used, listed below: 
· Various obstacles that affect the MA process. 
· Patent obstacles and complications that affect the overall time span. 
· Norway is a relatively small market and therefore less attractive for some generic 
companies. 
· Production issues and challenges faced by generic firms 
· In some cases, the substitution list and reimbursement scheme processes can cause 
delays to the overall time span. 
· Once the original drug patent expires, the original firms can choose to enter the 
stepped price system and create competition for generic firm, which causes a delay in 
entering the market.   
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7.Conclusion  
Generic drugs are an important element in health economy as they contribute to the decline of 
pharmaceutical prices. There are several processes required to complete before a generic drug 
can enter the market. For each of these processes, which are called phases in this paper, there 
are regulations that apply. These regulations need to be followed in order for a firm to enter 
the market. Before a generic drug enters the market the firm has to develop the drug, apply for 
MA, enter the substitution list in order to be financed by the NIS, and finally wait for the 
patent of the original drug to expire before it can enter the market. 
 
The sample data gathered from NoMA included 53 substances and each substance had an 
original as well as a generic drug present in the Norwegian market. The data analysis revealed 
that generally an original drug would be free of generic competition for 11 years on average 
Furthermore, once a generic firm applies for MA it takes 357 days (median) on average to get 
approval. Once approved MA, generic firms used 131 days (median) on average to enter the 
market.   
 
In addition to being a small market for pharmaceuticals compared to other European 
countries, generic companies experience a high competition to enter the Norwegian market, 
because of the vertical integrated market. It was claimed that these two reasons withdrew the 
generic firms from the Norwegian market.  
  
The findings of this paper might have an impact in the future of socio-economic analysis with 
regard to the real-price adjustment for pharmaceuticals. As highlighted earlier, the time span 
might be a contribution in evaluation of cost-effectiveness analysis in health care. The results 
obtained can provide public health decision-makers with useful information regarding the 
resource allocation. Potentially, these findings might be used by NoMA for the purpose of 
pharmaceutical reimbursement to compare the time-span results from this thesis with those 
presented by the pharmaceutical firm, in their pharmacoeconomic analysis. Particularly, when 
a comparative drug applies for reimbursement for the next 5 years. Subsequently, these results 
might help NoMA to estimate a more accurate price path prediction of the drug.  
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Regarding future studies, it would be desirable to conduct a follow-up study of time span 
including more data when these are available, in order to examine whether the trend of time 
span has altered or remained stable. Furthermore, a case study to investigate some substances 
in detail would be of great interest. Information about why some particular substances used 
less time to enter the market can be insightful and might alter the policy within the public 
health decision-makers and the pharmaceutical companies. This in combination with the 
findings presented here would probably lead to new effective solutions.    
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Appendix I  
 
 
Table 1: information about the substances and the days calculated in four phases included in 
the paper.   
ATC code Substance 
entered 
stepped 
price 
system  
Days from 
Original 
got MA to  
marketed 
Days 
from 
Generic 
applied 
to got 
MA 
Days 
from 
Generic 
got MA to 
Marketed 
Days from 
original to 
generic 
marketed 
N06AB06 Sertraline 01-nov-05 56,00 179,00 74,00 3137,00 
A02BC03 Lanzoprazole 01-mai-05 32,00 192,00 44,00 4079,00 
D01BA02 Terbinafine 01-mai-05 44,00 168,00 60,00 4048,00 
M01AC06 Meloxicam 01-sep-05 252,00 743,00 51,00 2984,00 
M05BA04 Alendronat 01-des-05 208,00 202,00 43,00 3167,00 
G04CA02 Tamsulosin 01-feb-06 47,00 195,00 72,00 2922,00 
N02CC01 Sumatripan 01-juni-06 29,00 203,00 351,00 4474,00 
A10BB12 Glimepiride 01-des-05 264,00 239,00 63,00 2983,00 
N05AX08 Risperidone 01-des-06 40,00 242,00 208,00 4110,00 
G04CB01 Finasteride 01-mai-07 21,00 160,00 78,00 5068,00 
C02AC05 Moxonidine 01-mai-07 202,00 237,00 76,00 2844,00 
N05AH04 Quetiapine 01-juni-07 557,00 531,00 45,00 1005,00 
N06AX16 Venlafaxine 01-juni-07 219,00 390,00 56,00 2783,00 
C07AB02 Metorpolol 01-okt-07 21,00 12,00 39,00 10834,00 
R01AD08 Fluticasone 01-apr-07 53,00 158,00 360,00 4976,00 
G02CB03 Kagergolin 01-juli-07 278,00 241,00 122,00 4929,00 
N04BC06 Kabergolin 01-juli-07 470,00 241,00 122,00 2952,00 
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ATC code Substance 
entered 
stepped 
price 
system  
Days from 
Original 
got MA to  
marketed 
Days 
from 
Generic 
applied 
to got 
MA 
Days 
from 
Generic 
got MA to 
Marketed 
Days from 
original to 
generic 
marketed 
N02AB03 Fenatyl 15-juli-05 81,00 158,00 165,00 3636,00 
A04AA01 Ondansetron 01-sep-05 20,00 245,00 104,00 5479,00 
A02BC02 Pantoprazol 01-des-07 111,00 392,00 161,00 4383,00 
N05AH03 Olanzapin 01-jan-08 88,00 449,00 42,00 2832,00 
L02BB03 Bicalutamid 01-aug-07 51,00 171,00 96,00 3864,00 
C10AA05 Atrovasatatin 15-nov-08 48,00 520,00 58,00 4049,00 
N06DA02 Donepezil 01-apr-09 104,00 379,00 85,00 3745,00 
A08AA10 Sibutramin 01-apr-09 30,00 650,00 157,00 2265,00 
N04BC04 Ropinirol 01-juni-09 160,00 454,00 429,00 3575,00 
C09CA01 Losartan 15-sep-09 24,00 335,00 64,00 4336,00 
C09DA01 Losartan og diuretisk 15-sep-09 51,00 671,00 251,00 4293,00 
J01CA08 Pivmecillinam 01-mai-09 60,00 461,00 130,00 8125,00 
N06DA03 Rivastigmin 01-des-09 106,00 268,00 198,00 3684,00 
C07AB07 Bisoprolol 
01-mars-
10 68,00 507,00 148,00 2635,00 
N06AB10 Escitalopram 
01-mars-
10 62,00 676,00 35,00 2724,00 
S01EE01 Latanoprost 01-apr-10 115,00 637,00 227,00 4534,00 
J05AB11 Valaciklovir 01-jan-10 397,00 334,00 132,00 4762,00 
L04AA06 Mykofenolatm 01-juli-10 312,00 192,00 984,00 2996,00 
C08CA13 Lerkanidipin 01-aug-10 119,00 459,00 454,00 3621,00 
L02BG03 Anastrozol 15-mai-10 41,00 1078,00 412,00 4853,00 
N02AA01 Morfinsulfat 15-jan-11 12,00 227,00 3416,00 9084,00 
D05AX02 Kalsipotriol 01-apr-11 28,00 1080,00 709,00 6849,00 
B01AC04 Klopidogrel 01-des-09 605,00 651,00 286,00 2066,00 
C09CA03 Valsartan 01-apr-10 214,00 230,00 193,00 2393,00 
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ATC code Substance 
entered 
stepped 
price 
system  
Days from 
Original 
got MA to  
marketed 
Days 
from 
Generic 
applied 
to got 
MA 
Days 
from 
Generic 
got MA to 
Marketed 
Days from 
original to 
generic 
marketed 
L01AX03 Temozolomid 01-juni-10 9,00 63,00 47,00 2207,00 
L02BG04 Letrozol 01-aug-11 141,00 416,00 193,00 4748,00 
L02BG06 Eksemestan 15-juli-11 91,00   4000,00 
N07BC01 Buprenorfin 23-des-10 75,00 498,00 93,00 4047,00 
C09DA03 Valsartan og  01-des-11 56,00 406,00 477,00 4293,00 
R06AX27 Desloratadin 
01-mars-
12 17,00 0,00 0,00 4046,00 
S01ED51 Latanoprost/Timorol 15-apr-12 86,00 595,00 866,00 3805,00 
C09CA06 Kandesartan 01-mai-12 129,00 567,00 102,00 4961,00 
C09DA06 
Kandesartan og 
Diuretica 01-mai-12 138,00 536,00 133,00 4138,00 
R03DC03 Montelukast 01-sep-12 86,00 658,00 1417,00 5053,00 
C09CA04 Irbesartan 01-sep-12 381,00 717,00 1009,00 2692,00 
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Appendix II  
Interview question guide  
The interview will not follow a tight program, but it will rather be like a conversation. The 
conversation shall start with questions about the experience with generic drugs related to the 
processes to enter the market. If the conversation deviates the questions below were used.  
1. When does generic firms apply for Market Authorisation (MT)  
2. What do you think about the time span used to approve MT?  
3. There are many generic products with MT but they have not entered the market yet, 
what may be the reason? What can be done to get these products to enter the market 
faster?  
4. Is it likely for original drugs with low turnover not to get generic competition because 
it will not be profitable?  
5. Do you make a conscious decision choice of applications with high profit above 
applications with low profit, when there are many applications? (Directed to NOMA)  
6. Can price regulation in Norwegian marked cause unwillingness to sell generic 
products in Norway?   
7. What are the reasons for waiting up to a year to enter the market after getting MA?  
8.  What do you think about the stepped price system?  
9. What would an ideal market for generics look like?  
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 Invitation to participate in an interview in relation to a Master Thesis 
I am a student at the Master´s programme Health Economics, Policy and Management at the 
University of Oslo, and I am at the moment working on my Master Thesis.  
The theme for the thesis is “Generic Competition in Pharmaceutical Industry, - how fast does 
generics get into the step price system?” The focus will be in studying the process and the 
time span between the dates of application for market authorization (MA) and the dates the 
step price is established. The aim of the study is to assess whether these processes and time 
spans are comparable between different drugs and can be formalized and used to predict price 
path (prisbaner) in analyses of health economy or cost effectiveness. The Norwegian 
Medicines Agency (NoMA) is responsible for setting maximum pharmacy purchase prices 
and maximum reimbursement price for affected medicines (both generic and original). A 
special price model is used for generics. Step price model (Trinprismodellen) is a scheme that 
ensures price fall in pharmaceuticals stepwise, by predefined rates. The model was introduced 
in January 2005 to reduce the costs of National Insurance Scheme. Pharmaceutical prices are 
important variables for cost effectiveness analysis. Many of these analyses have a time span 
of several years. Therefore prediction of pharmaceutical prices is a very important factor. The 
biggest change in future prices are as usually when generic competition is established.  
In order to complete my study I wish to interview those representatives at NoMA that work 
with market authorisation, step price and list of substitutable drugs (bytteliste). In addition I 
would like to interview representatives from the pharmaceutical industry that offer step price 
products, both suppliers of originators and generics.  
The method for collecting the needed information is collecting data from NoMA´s database 
and interviews where the informant will be able to tell his/her experiences with and opinion of 
the process. The interview will not follow a tight plan. I will use a tape recorder in addition to 
taking notes. This is to enhance the quality of the quotes, and the recording will be deleted 
after the project has been finished. The interview will take about one hour, and the informant 
can decide the time and place. The quotes that will be used, or specific opinions or 
perceptions that are emphasized greatly, will be checked with the informant before the thesis 
is handed in for evaluation. No names of informants will be used in the thesis.    
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Participation in the study is of course voluntary and the consent of the participation can be 
withdrawn as long as the study is in progress without any cause being needed. As a researcher 
I am a subject of confidentiality and must therefore treat all data confidentially.   
Feel free to contact me, or my supervisor if any question.  
 
Regards  
 
Vlora Kabashi  
Mob: 90040609 
Email: vlorak@studmed.uio.no 
 
Supervisor: Tor Iversen 
Email: tor.iversen@medisin.uio.no 
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Appendix III 
Statistical outputs from PASW Statistics (formerly SPSS) version 20  
 
Descriptive Statistics 
 N Minimum Maximum Mean Std. 
Deviation 
Variance Skewness 
Statistic Statistic Statistic Statistic Statistic Statistic Statistic Std. 
Error 
Phase_one 53 9 605 133,94 138,589 19206,978 1,819 ,327 
Phase_two 52 0 1080 390,56 238,133 56707,467 ,885 ,330 
Phase_tree 52 0 3416 293,83 526,249 276937,832 4,545 ,330 
Phase_four 53 1005 10834 4039,55 1697,701 2882188,829 1,881 ,327 
Valid N 
(listwise) 
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Statistical outputs for phase one  
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Statistical outputs for phase two 
 
 
 
 
Statistical outputs for phase three 
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Statistical outputs for phase four 
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